Kalbitor Approval History

  • FDA approved: Yes (First approved December 1st, 2009)
  • Brand name: Kalbitor
  • Generic name: ecallantide
  • Previous name: DX-88
  • Company: Dyax Corp.
  • Treatment for: Angioedema

Kalbitor (ecallantide) is plasma kallikrein inhibitor indicated for treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.

FDA Approval History for Kalbitor

DateArticle
Apr  7, 2014Approval FDA Approves Expanded Use of Kalbitor for the Treatment of HAE to Patients 12 Years of Age and Older
Dec  2, 2009Approval Dyax Announces FDA Approval of Kalbitor (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
Jun  8, 2009Dyax Announces FDA Accepts for Review the Complete Response Submission for DX-88 in Hereditary Angioedema
Mar 27, 2009Dyax Receives Complete Response Letter from FDA for DX-88 in Acute Attacks of Hereditary Angioedema
Feb  5, 2009FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
Jan 13, 2009Dyax Announces FDA Advisory Committee to Review DX-88 for Hereditary Angioedema
Nov 21, 2008FDA Accepts Filing and Grants Priority Review for DX-88 for Hereditary Angioedema
Sep 24, 2008Dyax Announces Completion of Biologics License Application for DX-88 for Hereditary Angioedema

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web3)